Arora et al.
Mechanism of Action of NSC18725 Against M. tuberculosis
Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A., and Duncan, K. (2002).
Evaluation of a nutrient starvation model of Mycobacterium tuberculosis
persistence by gene and protein expression profiling. Mol. Microbiol. 43, 717–
Bogatcheva, E., Hanrahan, C., Chen, P., Gearhart, J., Sacksteder, K., Einck, L., et al.
(2010). Discovery of dipiperidines as new antitubercular agents. Bioorg. Med.
Brodin, P., Poquet, Y., Levillain, F., Peguillet, I., Larrouy-Maumus, G., Gilleron,
M., et al. (2010). High content phenotypic cell-based visual screen identifies
Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in
Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 61:e00969-17.. doi:
Li, Y., Sun, F., and Zhang, W. (2019). Bedaquiline and delamanid in the treatment
of multidrug-resistant tuberculosis: Promising but challenging. Drug Dev. Res.
80, 98–105.
Li, H., Salinger, D. H., Everitt, D., Li, M., Del Parigi, A., Mendel, C., et al.
(2019). Long-term effects on QT prolongation of pretomanid, alone and in
combinations, in patients with tuberculosis. Antimicrob. Agents Chemother.
Lowrie, D. B., and Andrew, P. W. (1988). Macrophage antimycobacterial
Chandra, T., Garg, N., Lata, S., Saxena, K. K., and Kumar, A. (2010). Synthesis
of substituted acridinyl pyrazoline derivatives and their evaluation for anti-
Cho, S. H., Warit, S., Wan, B., Hwang, C. H., Pauli, G. F., and Franzblau,
S. G. (2007). Low-oxygen-recovery assay for high-throughput screening of
compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob.
Mak, P. A., Rao, S. P., Ping Tan, M., Lin, X., Chyba, J., Tay, J., et al. (2012).
A high-throughput screen to identify inhibitors of ATP homeostasis in non-
replicating Mycobacterium tuberculosis. ACS Chem. Biol. 7, 1190–1197. doi:
Maurya, H. K., Verma, R., Alam, S., Pandey, S., Pathak, V., Sharma, S., et al. (2013).
Studies on substituted benzo[h]quinazolines, benzo[g]indazoles, pyrazoles, 2,6-
diarylpyridines as anti-tubercular agents. Bioorg. Med. Chem. Lett. 23, 5844–
Christophe, T., Ewann, F., Jeon, H. K., Cechetto, J., and Brodin, P. (2010).
High-content imaging of Mycobacterium tuberculosis-infected macrophages:
an in vitro model for tuberculosis drug discovery. Future Med. Chem. 2,
Christophe, T., Jackson, M., Jeon, H. K., Fenistein, D., Contreras-Dominguez,
M., Kim, J., et al. (2009). High content screening identifies decaprenyl-
phosphoribose 2’ epimerase as a target for intracellular antimycobacterial
Daidone, G., Plescia, S., Raffa, D., Maggio, B., and Schillaci, D. (1992). Synthesis
and evaluation of antimicrobial activity of new 4-nitroso and 4-diazopyrazole
derivatives. Farmaco 47, 203–217.
Dara, Y., Volcani, D., Shah, K., Shin, K., and Venketaraman, V. (2019). Potentials
of host-directed therapies in tuberculosis management. J. Clin. Med. 8:E1166.
Dhiman, R., and Singh, R. (2018). Recent advances for identification of new
scaffolds and drug targets for Mycobacterium tuberculosis. IUBMB Life 70,
Mawatwal, S., Behura, A., Ghosh, A., Kidwai, S., Mishra, A., Deep, A., et al.
(2017). Calcimycin mediates mycobacterial killing by inducing intracellular
calcium-regulated autophagy in
a P2RX7 dependent manner. Biochim.
Mawatwal, S., Behura, A., Mishra, A., Singh, R., and Dhiman, R. (2018). Calcimycin
induced IL-12 production inhibits intracellular mycobacterial growth by
Moreira, W., Ngan, G. J., Low, J. L., Poulsen, A., Chia, B. C., Ang, M. J., et al.
(2015). Target mechanism-based whole-cell screening identifies bortezomib as
an inhibitor of caseinolytic protease in mycobacteria. MBio 6:e00253-15. doi:
Naim, M. J., Alam, O., Nawaz, F., Alam, M. J., and Alam, P. (2016). Current
status of pyrazole and its biological activities. J. Pharm. Bioallied Sci. 8, 2–17.
Odds, F. C. (2003). Synergy, antagonism, and what the chequerboard puts between
Paik, S., Kim, J. K., Chung, C., and Jo, E. K. (2019). Autophagy: a new strategy
for host-directed therapy of tuberculosis. Virulence 10, 448–459. doi: 10.1080/
Diacon, A. H., Pym, A., Grobusch, M. P., de los Rios, J. M., Gotuzzo, E., Vasilyeva,
I., et al. (2014). Multidrug-resistant tuberculosis and culture conversion with
bedaquiline. N. Engl. J. Med. 71, 723–732.
Early, J., Ollinger, J., Darby, C., Alling, T., Mullen, S., Casey, A., et al.
(2019). Identification of compounds with pH-Dependent bactericidal activity
against Mycobacterium tuberculosis. ACS Infect. Dis. 5, 272–280. doi: 10.1021/
Glaziou, P., Floyd, K., and Raviglione, M. C. (2018). Global epidemiology of
Pathak, V., Maurya, H. K., Sharma, S., Srivastava, K. K., and Gupta, A. (2014).
Synthesis and biological evaluation of substituted 4,6-diarylpyrimidines and
3,5-diphenyl-4,5-dihydro-1H-pyrazoles as anti-tubercular agents. Bioorg. Med.
Peddireddy, V., Doddam, S. N., and Ahmed, N. (2017). Mycobacterial dormancy
systems and host responses in tuberculosis. Front. Immunol. 8:84. doi: 10.3389/
Grant, S. S., Kawate, T., Nag, P. P., Silvis, M. R., Gordon, K., Stanley, S. A.,
et al. (2013). Identification of novel inhibitors of nonreplicating Mycobacterium
tuberculosis using a carbon starvation model. ACS Chem. Biol. 8, 2224–2234.
Horsburgh, C. R. Jr., Barry, C. E. III, and Lange, C. (2015). Treatment of
Tuberculosis. N. Engl. J. Med. 373, 2149–2160.
Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., et al. (2013). Discovery of
Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med.
Singh, R., Manjunatha, U., Boshoff, H. I., Ha, Y. H., Niyomrattanakit, P., Ledwidge,
R., et al. (2008). PA-824 kills nonreplicating Mycobacterium tuberculosis by
Singh, R., Singh, M., Arora, G., Kumar, S., Tiwari, P., and Kidwai, S. (2013).
Polyphosphate deficiency in Mycobacterium tuberculosis is associated with
enhanced drug susceptibility and impaired growth in guinea pigs. J. Bacteriol.
Karrouchi, K., Radi, S., Ramli, Y., Taoufik, J., Mabkhot, Y. N., Al-Aizari,
F. A., et al. (2018). Synthesis and pharmacological activities of pyrazole
derivatives:
a
Keche, A. P., Hatnapure, G. D., Tale, R. H., Rodge, A. H., and Kamble, V. M.
(2012). Synthesis, anti-inflammatory and antimicrobial evaluation of novel 1-
acetyl-3,5-diaryl-4,5-dihydro (1H) pyrazole derivatives bearing urea, thiourea
and sulfonamide moieties. Bioorg. Med. Chem. Lett. 22, 6611–6615. doi: 10.
Kidwai, S., Bouzeyen, R., Chakraborti, S., Khare, N., Das, S., Gosain, T. P., et al.
(2019). NU-6027 inhibits growth of Mycobacterium tuberculosis by targeting
Protein Kinase D and Protein Kinase G. Antimicrob. Agents Chemother.
Slack, W. A. F. A. R. (1957). Improvements in or Relating to Pyrazole Compounds
and Compositions Containing Them. United Kingdom Patent No GB786753A.
Munich: European Patent Office.
Snider, D. E. Jr., and Roper, W. L. (1992). The new tuberculosis. N. Engl. J. Med.
326, 703–705.
Stanley, S. A., Barczak, A. K., Silvis, M. R., Luo, S. S., Sogi, K., Vokes, M., et al.
(2014). Identification of host-targeted small molecules that restrict intracellular
Mycobacterium tuberculosis growth. PLoS Pathog. 10:e1003946. doi: 10.1371/
Kidwai, S., Park, C. Y., Mawatwal, S., Tiwari, P., Jung, M. G., Gosain, T. P.,
et al. (2017). Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against
Stanley, S. A., Grant, S. S., Kawate, T., Iwase, N., Shimizu, M., Wivagg, C., et al.
(2012). Identification of novel inhibitors of M. tuberculosis growth using whole
12